Evidence Paper Review

 Quick Explanation Copied

 Long Explanation

What the paper establishes — with strong convergent evidence

The central claim is that CIP2A harbors a previously undescribed druggable pocket (PDB 5UFL residues D477, K490, Q524, Q558) adjacent to the homodimerization surface, and that targeting it destabilizes CIP2A. The evidence chain is unusually complete for a pocket-discovery paper: dual computational prediction (Panther and P2Rank), MD simulation of the A476W mutation showing R557 shifting toward Q558 of the opposing monomer, in vitro GST pull-down confirming dimerization loss comparable to the known L533E interface mutant, reduced CIP2A-B56α binding, and full-length destabilization in 22RV1 cells matching the dimer-interface 3A mutant phenotype Pocket mutagenesis and stability data.

The GNA story is the strongest part: MST gives Kd = 780 ± 70 nM for GNA binding to CIP2A(1-560); SEC-MALS independently confirms dimer dissociation at 5–10x molar excess; fragment mapping shows the 331–560 pocket region is required for GNA sensitivity; and two independent "gatekeeper" mutations (L480W, S527W) blunt GNA's dimer-disrupting effect from ~80% to 40–50%, which is textbook pocket-validation logic GNA binding and gatekeeper mutant validation. Two GNA batches from independent manufacturers ruled out batch effects — a control many papers omit.

Reported MST Kd values from the preprint; error bar shown only for GNA, the only compound with a reported uncertainty.

Where skepticism is warranted

1. GNA selectivity is unresolved by design. The authors explicitly concede that GNA/GIA hit multiple oncogenic targets Explicit multitargeting concession, consistent with a prior structural study of gambogic acid binding an Hsp90β pocket CIP2A degrader multitargeting context. Consequently the cell-viability and endogenous-CIP2A-reduction data (MDA-MB-231, MDA-MB-436, 22RV1, HeLa) cannot be interpreted as CIP2A-specific effects — the authors say this plainly, which is honest but means the in cellulo pharmacology is correlative only Cellular CIP2A reduction data.

2. Fragment-based limitations. All structural and binding work uses CIP2A(1-560); full-length recombinant CIP2A remains intractable. Notably, a 2026 preprint shows full-length CIP2A forms tetramers via a C-terminal coiled coil (residues 884–892) required for TOPBP1 recruitment — a quaternary state invisible to the 1-560 construct used here CIP2A tetramerization preprint. This does not invalidate the pocket findings but means the dimer-centric structural model may understate CIP2A's oligomeric complexity in cells. The authors did test GST-CIP2A(331-905) and found GNA still works, which partially addresses the C-terminal tail concern.

3. Sample sizes and statistical power. Most quantifications use N = 3 biological repeats with Welch-corrected t-tests; cellular target engagement (bGNA pull-down) used only N = 2. These are adequate for directionality but not for precise effect-size estimation. No correction for multiple comparisons across the COSMIC mutation panel (five mutations tested) is reported.

4. Conflict of interest. OTP is founder/shareholder of Aurlide Ltd, a CIP2A-targeting company; the remaining authors declare no competing interests. This does not invalidate the biophysical data but warrants awareness in interpreting translational framing COI disclosure.

Significance and what would change the conclusion

CIP2A is a high-value target (synthetic lethal in BRCA/HRD cancers; implicated in AD pathogenesis), and no structural vulnerability had been demonstrated before — prior small-molecule "CIP2A inhibitors" lacked target-engagement evidence First CIP2A pocket evidence. The finding would be weakened if: (a) GNA binding to CIP2A(1-560) proves to be an artifact of the His-tag or non-native folding in the MST construct; (b) gatekeeper mutations fail to protect full-length endogenous CIP2A from GNA degradation in cells (the key missing experiment); or (c) independent groups cannot reproduce SEC-MALS dimer dissociation. Confidence: high on in vitro binding and dimer disruption; moderate on pocket causality; low-moderate on therapeutic translation given GNA polypharmacology and absent in vivo data.

Deep-Dive the Evidence Chain Design CIP2A PROTAC Strategy Predict GNA Off-Targets

Author Reviews: Explore full publication histories of key authors:

Karolina PavicJukka WestermarckOlli PentikäinenUlla PentikäinenPasi VirtaSami Kurkinen

 BGPT Paper Review

Study Novelty

First demonstrated druggable pocket on CIP2A, a target lacking any structural vulnerability evidence despite extensive oncology literature; GNA pocket-engagement with gatekeeper mutant validation is a genuinely new structural-pharmacology finding.

Scientific Quality

Methodologically rigorous (dual pocket predictors, MST + SEC-MALS + DSF orthogonal binding assays, two GNA batches, gatekeeper mutants). Deducted for N=3/N=2 replicates, no multiple-comparison correction on the COSMIC panel, fragment-only structural basis, and unaddressed selectivity of the tool compound.

Study Generality

Highly relevant to cancer (broad) and AD, but pocket findings are CIP2A-specific and the paradigm (targeting PPI-adjacent pockets to destabilize scaffold proteins) is already known; generalizable principles are moderate.

Study Usefulness

Opens structure-based CIP2A inhibitor/PROTAC development with defined coordinates and a validated tool compound; directly actionable for drug-discovery groups targeting HRD cancers and AD.

Study Reproducibility

Detailed methods (vectors, buffers, MST/DSF/SEC-MALS parameters, primer sequences) and PDB 5UFL access support reproduction; raw datasets are not publicly deposited and some reagents (DAP-19, MAD-28) were gifts.

Explanatory Depth

Mechanistic chain from pocket geometry → MD-predicted interface perturbation → dimer loss → B56α binding loss → protein destabilization is well-supported; deeper atomic-level understanding awaits a co-crystal or cryo-EM structure of GNA-bound CIP2A.